Department of Gastrointestinal Surgery, Zhongshan Hospital of Xiamen University, Xiamen, 361000, China.
Gastrointestinal Oncology Center of Xiamen University, Xiamen, 361000, China.
Updates Surg. 2022 Jun;74(3):999-1009. doi: 10.1007/s13304-022-01268-8. Epub 2022 Mar 24.
There are no ideal biomarkers including the TNM stage that can accurately predict the recurrence of colorectal cancer (CRC) and the benefit of chemotherapy for stage II patients. Here, 451 CRC patients were divided into three groups according to preoperative levels of prothrombin time (PT) and CEA to analyze the value of these indexes in predicting postoperative recurrence in different TNM stages. Preoperatively elevated levels of PT and CEA were significantly associated with a high 5-year cumulative recurrence rate (CRR) and short recurrence-free survival (RFS). According to PT and CEA levels, the 5-year CRR and RFS differed significantly among the High-risk (PT ≥ 12.65 s and CEA ≥ 10.175 ng/ml), Middle-risk (PT ≥ 12.65 s or CEA ≥ 10.175 ng/ml), and Low-risk (PT < 12.65 s and CEA < 10.175 ng/ml) groups (p < 0.001). In the same TNM stage, the 5-year CRR of the High-risk group was significantly higher and the RFS was markedly shorter than those in the Low-risk and even those in stage III (p < 0.001). In the subgroup of early stage (stage I and II), the 5-year CRR of the High-risk group was significantly higher and the RFS was significantly shorter than those in stage IIIA and IIIB (p < 0.001), which is similar to IIIC. In conclusion, preoperatively elevated levels of serum PT and CEA were reliable predictors of postoperative high-risk recurrence in CRC and combined with TNM stage precisely identify postoperative recurrence CRC patients in stage I-III and the benefit of adjuvant chemotherapy for patients with stage II CRC.
目前尚无理想的生物标志物(包括 TNM 分期)能够准确预测结直肠癌(CRC)的复发和 II 期患者化疗的获益。在这里,根据术前凝血酶原时间(PT)和 CEA 水平将 451 例 CRC 患者分为三组,以分析这些指标在预测不同 TNM 分期术后复发中的价值。术前升高的 PT 和 CEA 水平与高 5 年累积复发率(CRR)和短无复发生存(RFS)显著相关。根据 PT 和 CEA 水平,高风险(PT≥12.65 s 和 CEA≥10.175ng/ml)、中风险(PT≥12.65 s 或 CEA≥10.175ng/ml)和低风险(PT<12.65 s 和 CEA<10.175ng/ml)组之间的 5 年 CRR 和 RFS 差异有统计学意义(p<0.001)。在相同的 TNM 分期中,高风险组的 5 年 CRR 显著升高,RFS 明显短于低风险组,甚至短于 III 期(p<0.001)。在早期(I 期和 II 期)亚组中,高风险组的 5 年 CRR 显著升高,RFS 明显短于 IIIA 期和 IIIB 期(p<0.001),与 IIIC 期相似。总之,术前血清 PT 和 CEA 水平升高是 CRC 术后高危复发的可靠预测指标,与 TNM 分期相结合可准确识别 I-III 期 CRC 患者术后复发情况,并为 II 期 CRC 患者辅助化疗的获益提供指导。